Palvella Therapeutics Inc (PI6)
XMUN 
Summary
PI6 Chart
Palvella Therapeutics: FDA Handholding Makes The Regulatory Story Stronger
Palvella Therapeutics, Inc. advances QTORIN rapamycin for microcystic lymphatic malformations, completing NDA submission with strong Phase 3 data and FDA rolling review. Regulatory risk is now significantly reduced, with the FDA awarding a third year of OOPD funding post-positive Phase 3 results and no further efficacy studies required. PVLA's robust $250.6 million cash position supports manufacturing, regulatory, and launch efforts ahead of a targeted US commercial launch in H1 2027.
Palvella Therapeutics: First Approval Could Unlock A Rare-Disease Commercial Flywheel
Palvella advances QTORIN rapamycin, targeting microcystic lymphatic malformations, with positive Phase 3 SELVA data and a rolling NDA submission underway. PVLA leverages a repeatable regulatory and commercial platform, aiming to expand QTORIN across multiple mTOR-driven dermatological indications, supporting a multi-indication commercial flywheel. Strong liquidity from a recent $230M equity raise enables PVLA to invest in commercialization and pipeline expansion, mitigating typical small biotech funding risks.
Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands
Palvella Therapeutics NASDAQ: PVLA is advancing topical therapies for serious rare skin diseases and vascular malformations that lack FDA-approved treatments, with its lead candidate, QTORIN rapamycin, moving toward a planned New Drug Application submission for microcystic lymphatic malformations.
Palvella Therapeutics Inc (PI6) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Palvella Therapeutics Inc ever had a stock split?
Palvella Therapeutics Inc Profile
| Biotechnology Industry | Healthcare Sector | Wesley H. Kaupinen CEO | XMUN Exchange | US6979471090 ISIN |
| US Country | 29 Employees | - Last Dividend | 23 Apr 2024 Last Split | - IPO Date |
Overview
Pavella Therapeutics Inc. stands as a beacon of innovation within the biotechnology industry, dedicated to revolutionizing the treatment landscape for rare genetic disorders. This groundbreaking company distinguishes itself by focusing on the research and development of novel therapies aimed at addressing the plethora of unmet medical needs within the realm of genetic diseases. By harnessing the power of advanced biotechnological innovations, Pavella Therapeutics Inc. is not just a participant in the healthcare and pharmaceutical sectors but a trailblazer, advocating for precision medicine approaches and the creation of personalized therapies. Their mission is to scout the horizons of medical science, identifying and tackling niche areas often disregarded by the pharmaceutical giants. This singular focus allows them to offer a glimmer of hope and viable treatment avenues to patients who previously faced a future with sparse options. In the financial markets, their distinctive stance and pioneering efforts in specialized domains underscore their potential to effectuate profound impacts, enhancing the overall biotechnology landscape by deepening our understanding of genetic conditions and championing the development of targeted biotherapeutic solutions.
Products and Services
- Innovative Therapies for Rare Genetic Disorders
Pavella Therapeutics is at the forefront of developing cutting-edge treatments specifically designed to combat rare genetic disorders. Their research initiatives are geared towards creating therapies that are not only effective but also tailored to meet the individual needs of patients. This ensures a personalized treatment approach, greatly enhancing the chances of success and improving the quality of life for those affected.
- Advanced Biotechnological Innovations
At the core of Pavella Therapeutics' operations lies a commitment to biotechnological advancements. Through relentless pursuit of innovation, the company continually explores and adopts new technologies and methodologies. These efforts are aimed at advancing their capability to understand, diagnose, and treat genetic diseases more precisely. By doing so, Pavella Therapeutics remains a key player in pushing the boundaries of what is possible in the treatment of rare genetic conditions.
Contact Information
